Search the Newsreel

Persistent Asset Partners Ltd Makes New $4.57 Million Investment in BioMarin Pharmaceutical Inc. $BMRN

Persistent Asset Partners Ltd has made a new investment of $4.57 million in BioMarin Pharmaceutical Inc., acquiring 79,933 shares, which now constitutes 1.4% of its portfolio. BioMarin recently reported strong Q2 earnings, surpassing analyst estimates with $1.20 EPS and $989.71 million in revenue, and …

Monaco Asset Management SAM Invests $10.58 Million in BioMarin Pharmaceutical Inc. $BMRN

Monaco Asset Management SAM has invested $10.58 million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), acquiring 184,937 shares, making it their eighth-largest holding. This investment comes as BioMarin reported strong quarterly earnings, beating analyst estimates with $1.20 EPS and a 20% revenue increase year-over-year. Analysts generally …

UBS raises Acadia Pharmaceuticals stock price target on trial optimism

UBS has increased its price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $49 from $45, maintaining a Buy rating, due to increased optimism for its drug remlifanserin in Alzheimer’s disease psychosis. The firm raised its probability of success for remlifanserin to 50% and its …

Mizuho raises Amylyx stock price target to $30 on higher pricing

Mizuho has increased its price target for Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) shares to $30 from $24, while maintaining an Outperform rating, due to updated pricing assumptions for its lead asset, avexitide. The firm anticipates positive Phase 3 LUCIDITY study data for avexitide in late …

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter

NRx Pharmaceuticals reported its second-quarter 2026 financial results, highlighting significant progress in advancing its preservative-free ketamine ANDA towards FDA approval and commercialization. The company secured $22.3 million in gross proceeds from a public offering, ensuring over a year of operations, and expanded its clinical …

EyePoint’s DURAVYU misses primary endpoint in wet AMD trial

EyePoint, Inc. announced that its Phase 3 LUGANO trial for DURAVYU in wet AMD treatment failed to meet its primary endpoint, largely due to an asymmetric cohort of patients experiencing vision loss unrelated to wet AMD. Despite this, an ad hoc analysis showed non-inferiority …

Kratos and GE Aerospace’s GEK800 Engine Receives U.S. Military Type Designation F143-ZZ-100 and EMD Contract Award for JASSM

Kratos Defense & Security Solutions, Inc. Engine selected as a second-source propulsion system for the Joint Air-to-Surface Standoff Missile (JASSM), advancing the program to deliver small, low-cost, high-performance engines for missiles and uncrewed platforms SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Kratos Defense …

From Hikma Pharmaceuticals (LSE:HIK) To Spire Healthcare Group (LSE:SPI): What Is Separating Healthcare Stocks Today?

Aarey Drugs Q1 Results: Revenue up 145% YoY, net profit falls 60%

Dynatrace Announces Proposed Private Placement of $1.25 Billion of Exchangeable Senior Notes

Dynatrace LLC, a subsidiary of Dynatrace, Inc., plans a private placement of $1.25 billion in Exchangeable Senior Notes due 2031, with an option for initial purchasers to acquire an additional $187.5 million. The notes will be senior, unsecured obligations guaranteed by Dynatrace and exchangeable …

2,792 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Simplicity Wealth LLC

Simplicity Wealth LLC recently acquired 2,792 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $1.39 million during the second quarter. Vertex reported quarterly revenue of $3.33 billion, exceeding estimates, though its EPS of $4.73 narrowly missed consensus. The company holds a "Moderate Buy" rating …

Plato Investment Management Ltd Purchases Shares of 6,083 Vertex Pharmaceuticals Incorporated $VRTX

Plato Investment Management Ltd recently acquired 6,083 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $3 million during the second quarter. Other institutional investors have also increased their holdings, leading to institutions collectively owning 90.96% of the company's stock. Despite some insider selling, analysts …

Trivium Point Advisory LLC Takes Position in Vertex Pharmaceuticals Incorporated $VRTX

Trivium Point Advisory LLC has acquired a new stake in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 2,199 shares valued at approximately $1.092 million during the second quarter. Other institutional investors have also recently adjusted their holdings in the pharmaceutical company, which reported quarterly earnings that narrowly …

How Is Computacenter (LSE:CCC) Converting The Global AI Hardware Cycle Into UK-Listed Revenue?

York Space Systems Inc. (NYSE:YSS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Gemini Space Station, Inc. (NASDAQ:GEMI) Analysts Are Cutting Their Estimates: Here's What You Need To Know

HBK Sorce Advisory LLC Invests $2.53 Million in Medpace Holdings, Inc. $MEDP

HBK Sorce Advisory LLC has invested $2.53 million in Medpace Holdings, Inc. (NASDAQ:MEDP) by purchasing 4,309 shares during the second quarter. This move comes as Medpace exceeded its quarterly earnings and revenue expectations, despite insiders selling approximately $38.0 million worth of stock in the …

Does BioMarin’s Raised 2026 Outlook and ESOP Shelf Offering Reshape the Bull Case for BMRN?

Earlier this month, BioMarin Pharmaceutical reported second-quarter 2026 results showing revenue of US$989.71 million and updated earnings guidance for the second half and full year, including a slight increase in its 2026 revenue outlook to US$3.88 billion–US$3.93 billion. Alongside these results, BioMarin filed a …

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Corbus Pharmaceuticals Holdings, Inc. announced inducement equity awards granted to Leonardo Nicacio, the new Chief Medical Officer, under Nasdaq Listing Rule 5635(c)(4). These grants include a nonstatutory stock option to purchase 191,676 shares and restricted stock units for 58,333 shares, both vesting over four …

IMC Chicago LLC Buys New Shares in Honeywell Aerospace $HONA

GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL

GSA Capital Partners LLP has acquired a new stake of 374,260 shares in Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL), valued at approximately $1.815 million. This purchase makes GSA Capital Partners LLP the owner of 0.53% of Zentalis Pharmaceuticals. Other institutional investors also made significant moves in …

GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD

GSA Capital Partners LLP has initiated a new investment in ACADIA Pharmaceuticals Inc., purchasing 70,484 shares valued at approximately $1.78 million during the second quarter. This move is part of a broader trend, with several other hedge funds also adjusting their positions in the …

Medpace Holdings, Inc. (MEDP) Stock Analysis: Navigating Growth with a Strong 162.15% Return on Equity

Medpace Holdings, Inc. (MEDP), a key player in the Healthcare Diagnostics & Research industry, demonstrates robust financial health with a 162.15% Return on Equity and 17.20% revenue growth, leading to a strong financial footing. Despite a "hold" consensus from analysts, technical indicators suggest a …

GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX

GSA Capital Partners LLP has acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), purchasing 62,775 shares valued at approximately $1.37 million during the second quarter. This move comes as several other institutional investors also increased their holdings in the company. Despite missing revenue …

Free float of Howmet Aerospace Inc. – BCS:HWM1

This article focuses on the "Free float" metric for Howmet Aerospace Inc., traded under the ticker HWM1 on the Santiago Stock Exchange (BCS). It provides a specific period value, change, and change percentage for this financial data point. The content appears to be a …

Howmet Aerospace stock holds near record highs as strong Q2 earnings lift 2026 outlook

Howmet Aerospace (HWM) stock is trading near its 12-month high following strong Q2 2026 results, which included double-digit revenue and EPS growth, and an upgraded full-year outlook. The company reported $2.55 billion in revenue and $1.33 EPS for Q2, beating analyst estimates, and raised …

Extra Space Storage stock holds steady as Q2 2026 funds from operations rise

Extra Space Storage Inc. (ISIN US30225T1025) reported higher revenue, earnings, and funds from operations for Q2 2026, leading management to raise full-year guidance. Despite the positive financial results, the stock traded steadily near $148, close to the consensus "Hold" rating and price target of …

Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging to form a leading CNS-focused biopharmaceutical company. This tax-free merger of equals anticipates $125 million in annual cost synergies within the first year and will create a combined portfolio of 11 medicines across addiction, ADHD, depression, and …

522,900 Shares in Treace Medical Concepts, Inc. $TMCI Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC acquired 522,900 shares of Treace Medical Concepts, Inc. ($TMCI) in the first quarter, valued at approximately $701,000, giving them a 0.81% stake. Other institutional investors also adjusted their holdings, with hedge funds and institutions collectively owning 84.08% of the company. Despite …

Talkspace, Inc.(NasdaqCM:TALK) dropped from S&P Health Care Services Select Industry Index

Talkspace, Inc. (NasdaqCM:TALK) has been removed from the S&P Health Care Services Select Industry Index. This news follows several other announcements of the company being dropped from various Russell and S&P indices around the same time. Talkspace is a virtual behavioral healthcare company offering …

Flputnam Investment Management Co. Invests $19.93 Million in Vertex Pharmaceuticals Incorporated $VRTX

Flputnam Investment Management Co. has acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), purchasing 40,116 shares valued at approximately $19.93 million during the second quarter. Other institutional investors have also adjusted their holdings in the pharmaceutical company. Analyst ratings for VRTX are generally …

Global Retirement Partners LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

Global Retirement Partners LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX) during the second quarter, purchasing 3,925 shares valued at approximately $1,950,000. Several other institutional investors also adjusted their holdings in the pharmaceutical company. Vertex Pharmaceuticals has a market capitalization of $128.36 …

20,864 Shares in Honeywell Aerospace $HONA Purchased by Flputnam Investment Management Co.

Flputnam Investment Management Co. Buys New Shares in Honeywell Aerospace $HONA

German American Bancorp Inc. Invests $3.59 Million in Honeywell Aerospace $HONA

Neuren Pharmaceuticals (ASX:NEU) Shares in Focus as DAYBUE Growth Supports Higher Royalty Outlook